skip to main content

Refractory idiopathic overactive bladder with urgency urinary incontinence — MSRA MCQ

Instant feedback + full explanation. One question, done properly.

HardLUTSRefractory idiopathic overactive bladder with urgency urinary incontinenceMSRA

A 69-year-old woman has urgency urinary incontinence, daytime frequency and nocturia. She has no leakage with coughing or exertion. Urine culture is negative, pelvic examination shows no prolapse, and post-void residual volume is 35 mL. A 3-day bladder diary shows frequent small-volume voids associated with urgency. She completed a 6-week bladder-training programme without satisfactory benefit. Sequential 8-week trials of tolterodine and solifenacin were ineffective, and subsequent adequately adherent trials of mirabegron and vibegron also gave insufficient improvement. She wishes to discuss invasive treatment. What is the most appropriate next management step?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Refer for urodynamic investigation and an MDT discussion of invasive options

Explanation lettering: E = shown as A · D = shown as B · B = shown as C · C = shown as D · A = shown as E

This is refractory overactive bladder (OAB): urgency urinary incontinence with frequency and nocturia, without stress leakage, infection, prolapse or clinically significant incomplete emptying. She has completed appropriate first-line bladder training and has had adequate trials of both anticholinergic and beta-3 agonist treatments. NICE advises referral to secondary care when OAB medicines have not been successful or tolerated. Before invasive treatment is selected, NICE recommends urodynamic investigation in women with OAB unresponsive to non-surgical and pharmacological management who wish to discuss further options. Demonstrating detrusor overactivity directs subsequent treatment, including consideration of botulinum toxin A after local MDT review. A is inappropriate because repeating the same completed conservative programme alone is unlikely to address severe refractory symptoms. B is inappropriate because further empirical anticholinergic escalation is not the preferred next step after two anticholinergic trials and beta-3 agonist failure; immediate-release oxybutynin also has an unfavourable adverse-effect profile in older people. C bypasses the required diagnostic and MDT sequence. E may be considered only within a specialist pathway after MDT review and is not a direct primary-care next step.

Reference: NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management (Last updated 24 June 2019; checked 15 August 2026) — https://www.nice.org.uk/guidance/ng123/chapter/Recommendations NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management (Last updated 24 June 2019; checked 15 August 2026) — https://www.nice.org.uk/guidance/ng123/chapter/Recommendations